EU-Japan Biotech & Pharma Partnering Conference 2026

16 Sept – 5 Oct 2026 | Osaka, Japan

HomeAgenda
Register
Register
Register

NextCell Pharma AB

Company (SME/startup) / 中小企業・スタートアップ

www.nextcellpharma.comHuddinge, Sweden
43 profile visits

About

NextCell Pharma is a Swedish clinical-stage biotechnology company developing allogeneic mesenchymal stromal cell therapies for immune-mediated diseases. Our lead program, NXTCL-T1D™, is being developed as a disease-modifying treatment for type 1 diabetes, with the aim of preserving endogenous insulin production through controlled immunomodulation. The proprietary NXTCL™ platform combines donor selection, scalable GMP manufacturing and cryopreserved off-the-shelf products designed for consistent potency and practical clinical use. NXTCL-T1D has been evaluated in clinical trials with long-term follow-up beyond five years. NextCell is advancing its clinical and regulatory strategy in Japan and seeking strategic collaborations for development and commercialization in Japan and broader Asia.

Social media

Business Domain / 分野

Pharmaceuticals / 医薬品Healthcare / ヘルスケア

Business Type / 業種

R&D / 研究開発

Disease Area / 疾患領域

Immunology / 免疫・炎症Metabolic diseases / 代謝

Modalities / モダリティ

Cell therapy /細胞治療

Technologies / 技術

Others / その他

Additional Information

Researched company/organisation type / マッチングご希望企業・機関のタイプ

Companies and Academia etc. (Joint research and development purpose) / 企業やアカデミア等(共同での研究、開発を目的)Companies and Entities (Providing your services or technology to your clients) / 技術・サービス(研究、開発、製造等の提供を目的)

Researched disease area / マッチングご希望の疾患領域

Immunology / 免疫・炎症Metabolic diseases / 代謝

Researched Modality / マッチングご希望のモダリティ

Cell therapy / 細胞治療

Researched Technologies / マッチングご希望の技術

Others /その他